Loading organizations...
Crescendo Bioscience is a South San Francisco, California-based healthcare organization that develops molecular diagnostic tests and software tools for rheumatologists to manage autoimmune and inflammatory diseases. The enterprise's core product, Vectra DA, functions as a protein-based blood test that quantifies rheumatoid arthritis disease activity, while digital platforms like VectraView and MyRA provide physicians and patients with tracking insights. Prior to its strategic exit, the company achieved significant clinical scale by processing 27,000 patient samples during the fourth quarter of 2013. In early 2014, the business was acquired by Myriad Genetics for a total valuation of $270 million, subsequently operating as a wholly owned subsidiary. Key executives who guided the organization's clinical and commercial development included William Hagstrom, David Chernoff, and Elena Hitraya. The diagnostic testing company was originally founded in July of 2002.
Crescendo Bioscience has raised $168.0M across 5 funding rounds.
Crescendo Bioscience has raised $168.0M in total across 5 funding rounds.
Crescendo Bioscience has raised $168.0M in total across 5 funding rounds.
Crescendo Bioscience's investors include Gary Kurtzman, MD, Leon Chen, Kleiner Perkins, Wildcat Ventures, Abhas Gupta, Aeris Capital, Mohr Davidow Ventures, Pete Meldrum.
Crescendo Bioscience has raised $168.0M across 5 funding rounds. Most recently, it raised $28.0M Series D in January 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2013 | $28M Series D | Gary Kurtzman, MD, Leon Chen | Kleiner Perkins, Wildcat Ventures, Abhas Gupta, Aeris Capital, Mohr Davidow Ventures | Announced |
| Sep 10, 2011 | $56M Debt Financing | Aeris Capital | Kleiner Perkins, Mohr Davidow Ventures, Pete Meldrum | Announced |
| Sep 1, 2011 | $31M Series C | — | Kleiner Perkins, Wildcat Ventures, Abhas Gupta | Announced |
| Jul 1, 2010 | $38M Series B | — | Kleiner Perkins, Abhas Gupta | Announced |
| Jun 1, 2008 | $15M Series B | — | Kleiner Perkins, Abhas Gupta | Announced |
Crescendo Bioscience is a molecular diagnostics company specializing in rheumatology, developing quantitative, objective blood tests to deliver deeper clinical insights for managing patients with autoimmune and inflammatory diseases.[1][2][3] It serves rheumatologists and healthcare providers treating conditions like rheumatoid arthritis, enabling more effective patient management through precise diagnostics.[1][2] The company raised $130.35M before being acquired by Myriad Genetics in February 2014, after which it operated as a wholly-owned subsidiary focused on inflammatory and autoimmune disease testing.[1][4]
Founded in 2002 and based in South San Francisco, California (formerly Riley Genomics), Crescendo Bioscience addressed gaps in rheumatology diagnostics by providing tools for objective disease assessment, though post-acquisition growth integrated into Myriad's broader portfolio with no recent independent momentum reported.[1][3]
Crescendo Bioscience was founded in July 2002 in South San Francisco, California, initially as Riley Genomics, with a focus on molecular diagnostics for rheumatology.[1][3] The core idea emerged from the need for quantitative blood tests to give rheumatologists actionable insights into autoimmune and inflammatory diseases, where traditional methods lacked precision.[1][2] Early traction built on this innovation, leading to $130.35M in funding and positioning it as a leader in the space before its acquisition by Myriad Genetics in February 2014.[1][3][4] Specific founders are not detailed in available records, but the company's evolution centered on expanding gene expression-based testing for immune-related conditions.[1]
Crescendo Bioscience rode the early 2000s wave of molecular diagnostics in personalized medicine, particularly for immunology, where gene expression profiling addressed unmet needs in autoimmune disease monitoring amid rising chronic inflammatory conditions.[1][3] Timing aligned with advances in blood-based biomarkers, influencing healthcare by shifting rheumatology toward data-driven care and paving the way for similar tools in transplants and gastroenterology (e.g., competitors like XDx and Glycominds).[1] As part of Myriad Genetics, it contributed to the ecosystem's push for precision diagnostics, amplifying market forces like regulatory emphasis on objective testing in an aging population with high autoimmune prevalence.[1][4]
Integrated into Myriad Genetics since 2014, Crescendo Bioscience's standalone trajectory has stabilized within a larger diagnostics powerhouse, with future growth tied to Myriad's expansions in oncology and hereditary testing amid AI-enhanced biomarker trends.[1][4] Evolving immuno-diagnostics and multi-omics will shape its role, potentially amplifying influence in rheumatology through next-gen sequencing. This positions it to deepen impact in personalized autoimmune care, echoing its original mission of objective insights in a maturing biotech landscape.[1][3]
